ADCC-R-Epo-R T-cells therapy(National University Hospital)

N/A

Report date: 2023/09/11 20:05:57

Base Information

Drug NameADCC-R-Epo-R T-cells therapy(National University Hospital)

Drug Alias NameAutologous T Cells Expressing an Antibody-dependent Cell Cytotoxicity Receptor (ADCC-R) and an Erythropoietin Receptor (Epo-R) therapy(National University Hospital)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsErythropoietin receptor modulators

TargetsErythropoietin receptor

Therapy Area/IndicationsSolid tumoursBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational University Hospital (Singapore)

China Registration ClassN/A

Develop Information

Active CompaniesNational University Hospital (Singapore)

Inactive CompaniesN/A

Active IndicationsSolid tumoursBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A